Imlifidase
Idefirix (imlifidase) is an enzyme pharmaceutical. Imlifidase was first approved as Idefirix on 2020-08-25. It has been approved in Europe to treat immunologic desensitization and kidney transplantation.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
30 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney transplantation | D016030 | — | — | — | 2 | 2 | — | 1 | 5 |
| Syndrome | D013577 | — | — | — | 2 | 1 | — | — | 3 |
| Anti-glomerular basement membrane disease | D019867 | EFO_0007290 | M31.0 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 3 | — | — | — | 3 |
| Graft rejection | D006084 | — | — | — | 1 | — | — | 1 | 2 |
| Renal insufficiency | D051437 | — | N19 | — | 1 | — | — | 1 | 2 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 2 | — | — | — | 2 |
| Guillain-barre syndrome | D020275 | EFO_0007292 | G61.0 | — | 1 | — | — | — | 1 |
| Thrombotic thrombocytopenic purpura | D011697 | — | M31.19 | — | 1 | — | — | — | 1 |
| Thrombocytopenic purpura | D011696 | — | — | — | 1 | — | — | — | 1 |
| Purpura | D011693 | HP_0000979 | D69.2 | — | 1 | — | — | — | 1 |
| Retinal diseases | D012164 | — | H35.9 | 1 | 1 | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | 1 | — | — | — | — | 1 |
| Muscular dystrophies | D009136 | EFO_0000757 | G71.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Imlifidase |
| INN | imlifidase |
| Description | Imlifidase, brand name Idefirix, is a medication for the desensitization of highly sensitized adults needing kidney transplantation, but unlikely to receive a compatible transplant.
|
| Classification | Enzyme |
| Drug class | enzymes |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1947415-68-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297981 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB15258 |
| UNII ID | UVJ7NL8S2P (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,516 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,719 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use